These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 34671620)

  • 1. Recent Advances of WEE1 Inhibitors and Statins in Cancers With p53 Mutations.
    Meng X; Gao JZ; Gomendoza SMT; Li JW; Yang S
    Front Med (Lausanne); 2021; 8():737951. PubMed ID: 34671620
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gain-of-function mutant p53 in cancer progression and therapy.
    Zhang C; Liu J; Xu D; Zhang T; Hu W; Feng Z
    J Mol Cell Biol; 2020 Sep; 12(9):674-687. PubMed ID: 32722796
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The interplay between mutant p53 and the mevalonate pathway.
    Parrales A; Thoenen E; Iwakuma T
    Cell Death Differ; 2018 Mar; 25(3):460-470. PubMed ID: 29238070
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DNAJA1 controls the fate of misfolded mutant p53 through the mevalonate pathway.
    Parrales A; Ranjan A; Iyer SV; Padhye S; Weir SJ; Roy A; Iwakuma T
    Nat Cell Biol; 2016 Nov; 18(11):1233-1243. PubMed ID: 27775703
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proteasomal and autophagy-mediated degradation of mutp53 proteins through mitochondria-targeting aggregation-induced-emission materials.
    Wang M; Yang Z; Song Y; Wei P; Ishiwme N; Wang L; Zhang H; Jing M; Gao M; Wen L; Zhang Y
    Acta Biomater; 2022 Sep; 150():402-412. PubMed ID: 35931280
    [TBL] [Abstract][Full Text] [Related]  

  • 6. AZD1775 Increases Sensitivity to Olaparib and Gemcitabine in Cancer Cells with p53 Mutations.
    Meng X; Bi J; Li Y; Yang S; Zhang Y; Li M; Liu H; Li Y; Mcdonald ME; Thiel KW; Wen KK; Wang X; Wu M; Leslie KK
    Cancers (Basel); 2018 May; 10(5):. PubMed ID: 29783721
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of a druggable protein-protein interaction site between mutant p53 and its stabilizing chaperone DNAJA1.
    Tong X; Xu D; Mishra RK; Jones RD; Sun L; Schiltz GE; Liao J; Yang GY
    J Biol Chem; 2021; 296():100098. PubMed ID: 33208462
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Key roles of Rho GTPases, YAP, and Mutant P53 in anti-neoplastic effects of statins.
    Ji L; Liu C; Yuan Y; Gao H; Tang ZX; Yang Z; Liu ZT; Jiang GH
    Fundam Clin Pharmacol; 2020 Feb; 34(1):4-10. PubMed ID: 31241783
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutant p53-ENTPD5 control of the calnexin/calreticulin cycle: a druggable target for inhibiting integrin-α5-driven metastasis.
    Pavlakis E; Neumann M; Merle N; Wieboldt R; Wanzel M; Ponath V; Pogge von Strandmann E; Elmshäuser S; Stiewe T
    J Exp Clin Cancer Res; 2023 Aug; 42(1):203. PubMed ID: 37563605
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutant p53 in Cancer Progression and Targeted Therapies.
    Zhu G; Pan C; Bei JX; Li B; Liang C; Xu Y; Fu X
    Front Oncol; 2020; 10():595187. PubMed ID: 33240819
    [No Abstract]   [Full Text] [Related]  

  • 11. Pontin, a new mutant p53-binding protein, promotes gain-of-function of mutant p53.
    Zhao Y; Zhang C; Yue X; Li X; Liu J; Yu H; Belyi VA; Yang Q; Feng Z; Hu W
    Cell Death Differ; 2015 Nov; 22(11):1824-36. PubMed ID: 25857266
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mutant p53 drives the loss of heterozygosity by the upregulation of Nek2 in breast cancer cells.
    Ghaleb A; Padellan M; Marchenko N
    Breast Cancer Res; 2020 Dec; 22(1):133. PubMed ID: 33267874
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The ubiquitin ligase TRIM21 regulates mutant p53 accumulation and gain of function in cancer.
    Liu J; Zhang C; Xu D; Zhang T; Chang CY; Wang J; Liu J; Zhang L; Haffty BG; Zong WX; Hu W; Feng Z
    J Clin Invest; 2023 Mar; 133(6):. PubMed ID: 36749630
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gain-of-Function (GOF) Mutant p53 as Actionable Therapeutic Target.
    Schulz-Heddergott R; Moll UM
    Cancers (Basel); 2018 Jun; 10(6):. PubMed ID: 29875343
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Gain-of-Function p53 R248W Mutant Promotes Migration by STAT3 Deregulation in Human Pancreatic Cancer Cells.
    Klemke L; Fehlau CF; Winkler N; Toboll F; Singh SK; Moll UM; Schulz-Heddergott R
    Front Oncol; 2021; 11():642603. PubMed ID: 34178628
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutant p53 in Cancer: Accumulation, Gain-of-Function, and Therapy.
    Yue X; Zhao Y; Xu Y; Zheng M; Feng Z; Hu W
    J Mol Biol; 2017 Jun; 429(11):1595-1606. PubMed ID: 28390900
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibitors of cell cycle checkpoint target Wee1 kinase - a patent review (2003-2022).
    Yan J; Zhuang L; Wang Y; Jiang Y; Tu Z; Dong C; Chen Y; Zhu Y
    Expert Opin Ther Pat; 2022 Dec; 32(12):1217-1244. PubMed ID: 36620912
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutant p53 Gain-of-Function: Role in Cancer Development, Progression, and Therapeutic Approaches.
    Alvarado-Ortiz E; de la Cruz-López KG; Becerril-Rico J; Sarabia-Sánchez MA; Ortiz-Sánchez E; García-Carrancá A
    Front Cell Dev Biol; 2020; 8():607670. PubMed ID: 33644030
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DNAJA1- and conformational mutant p53-dependent inhibition of cancer cell migration by a novel compound identified through a virtual screen.
    Nishikawa S; Kaida A; Parrales A; Ranjan A; Alalem M; Ren H; Schoenen FJ; Johnson DK; Iwakuma T
    Cell Death Discov; 2022 Oct; 8(1):437. PubMed ID: 36316326
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Statin as anti-cancer therapy in autochthonous T-lymphomas expressing stabilized gain-of-function mutant p53 proteins.
    Tutuska K; Parrilla-Monge L; Di Cesare E; Nemajerova A; Moll UM
    Cell Death Dis; 2020 Apr; 11(4):274. PubMed ID: 32332697
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.